Every material Form 8-K Phibro Animal Health filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Phibro Animal Health disclosed that Rob Aukerman will retire as President, North America Region, effective December 31, 2024, and will stay on in an advisory role until June 30, 2025. Todd Armstrong, currently Vice President of the US Ruminant Business, will succeed him as President, North American Region, effective January 1, 2025. The filing describes a planned transition rather than a financial change.
Rob Aukerman notified the company on November 7, 2024 that he will retire effective December 31, 2024
Aukerman will continue in an advisory capacity until June 30, 2025
Todd Armstrong, Vice President of the US Ruminant Business since 2020, will be promoted to President, North American Region, effective January 1, 2025
Phibro Animal Health reported fiscal first-quarter results for the period ended September 30, 2024, with net sales up 13% to $260.4 million and net income of $7.0 million, compared with a net loss of $8.0 million a year earlier. The company also updated its fiscal 2025 guidance, which excludes the pending Zoetis Medicated Feed Additive acquisition, and shareholders re-elected two directors and ratified PricewaterhouseCoopers as auditor at the November 5 annual meeting.
Net income of $7.0 million, or $0.17 per diluted share, versus a net loss of $8.0 million in the year-earlier quarter
Adjusted EBITDA of $30.7 million, up 64% from $18.7 million
Fiscal 2025 guidance: net sales of $1.05 billion to $1.10 billion and adjusted EBITDA of $124 million to $132 million, excluding the Zoetis portfolio
At the November 5, 2024 annual meeting, Mary Lou Malanoski and Carol A Wrenn were elected as Class II directors and PwC was ratified for fiscal 2025
Phibro Animal Health completed its acquisition of Zoetis's medicated feed additive product portfolio and certain water-soluble products on October 31, 2024, for $350 million in cash, subject to adjustments. The company funded the purchase by borrowing $350 million under its July 3, 2024 Credit Agreement. The company expects the portfolio to boost profitability and EBITDA margin and to be accretive to Adjusted EPS, but the filing gives no specific figures and says more financial details will come at the Q1 earnings call on November 7.
Purchase price of $350 million in cash, subject to adjustments set out in the Purchase Agreement
Funded by $350 million of borrowings: $189 million of Delayed Draw Term A-1 Loans and $161 million of Delayed Draw Term A-2 Loans
Portfolio includes more than 37 product lines sold in about 80 countries, six manufacturing sites and more than 300 employees
Company expects accretion to Adjusted EPS; further financial details due on the Q1 earnings call on November 7
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Phibro Animal Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →